Transaction DateRecipientSharesTypePriceValue
22nd December 2020William Garrett Gray2,406Open or private sale$2.79$6,712.50
14th December 2020Lindsay A Md Rosenwald100,000Open or private purchase$2.66$266,000.00
26th August 2020Lindsay A Md Rosenwald52,500Open or private purchase$18.00$945,000.00
14th July 2020Lindsay A Md Rosenwald16,611Grant/award etc.$0.00
14th July 2020Neil Herskowitz16,611Grant/award etc.$0.00
14th July 2020Michael S Weiss16,611Grant/award etc.$0.00
22nd June 2020Michael S Weiss1,556,029Grant/award etc.$0.00
16th June 2020Neil Herskowitz10,000Grant/award etc.$0.00
5th June 2020Lindsay A Md Rosenwald24,390Grant/award etc.$0.00
5th June 2020Michael S Weiss24,390Grant/award etc.$0.00
Checkpoint Therapeutics
Checkpoint Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company was founded on November 10, 2014 and is headquartered in New York.

Ticker: CKPT
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1651407
Employees: 8
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $22 M (-15%)
Other Assets, Current: $42 Th (61%)
Assets, Current: $23 M (-15%)
Assets: $23 M (-15%)
Accounts Payable, Current: $2 M (-24%)
Liabilities, Current: $8 M (0%)
Liabilities: $8 M (-5%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $51 M (8%)
Retained Earnings (Accumulated Deficit): $128 M (0%)
Stockholders' Equity (Parent): $15 M (0%)
Liabilities and Equity: $23 M (-15%)
Research and Development: $3 M (-46%)
General and Administrative Expenses: $2 M (-49%)
Operating Income/Loss: $5 M (-41%)
Other Income, net: $29 Th (-67%)